Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BEIGENE, LTD.
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
10/11BEIGENE : Brukinsa Approved in Australia for Mantle Cell Lymphoma
MT
10/10BeiGene Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mant..
CI
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/10BEIGENE : Announces BRUKINSA« (Zanubrutinib) Approved for Treatment of Patients with Mantl..
BU
10/08BEIGENE : Drug for Waldenstrom's Macroglobulinemia Wins Regulatory Nod in Australia
MT
More most relevant news
All news about BEIGENE, LTD.
10/21INSIDER SELL : Beigene
MT
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/21BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma
MT
10/20BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho..
MT
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/20Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm..
CI
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/14BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl
CI
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
More news
News in other languages on BEIGENE, LTD.
10/21VENTE PAR UN INITIÉ : Beigene
10/21La Russie approuve le médicament anticancéreux de BeiGene pour le traitement du lymphom..
10/11Le Brukinsa de BeiGene approuvé en Australie pour le lymphome à cellules du manteau
10/08Le médicament de Beigene contre la macroglobulinémie de Waldenstrom reçoit le feu vert ..
09/24Leap Therapeutics lève 104 millions de dollars après avoir réalisé une offre de titres ..
09/21BeiGene ajouté aux indices FTSE Russell
09/20BeiGene obtient un avis positif de l'autorité européenne de réglementation des médicame..
09/17Les ADR asiatiques en baisse vendredi
09/17PUMP / DUMP #29 : Les Tops & Flops de la semaine
09/17ATTENTION - RECTIFICATION : BeiGene a reçu un avis favorable du Comité des médicaments à u..
More news
Analyst Recommendations on BEIGENE, LTD.
10/14BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
10/12BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
08/16BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $407 From $409, Maintains Over..
MT
06/14BEIGENE : SVB Leerink Adjusts BeiGene's Price Target to $417 from $388, Keeps Outperform R..
MT
06/03BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $409 From $357, Maintains Over..
MT
More recommendations
Press releases
10/21BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
PU
10/21BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
10/20BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA« (Zanubrutinib) for Treatme..
BU
10/13BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA« (Zanubrutinib) fo..
PU
10/13BEIGENE, LTD. : Termination of a Material Definitive Agreement, Other Events, Financial St..
AQ
More press releases
Upcoming event on BEIGENE, LTD.
11/11/21